Journal of Biological Chemistry · 2011 · 39 citations · 39 references
Life SciencesMicrobiologyMolecular BiologyBacteriologyHost-pathogen InteractionsInnate ImmunityBacterial ImmunologyBacterial InfectionsBacterial PathogenesisBacterial Virulence FactorsInnate Immune RecognitionMicrobial Virulence FactorsAntibacterial Host ResponseBacterial Lipopolysaccharide RecognitionC-terminal Domain StructureComplement-mediated Bacterial KillingGram-negative Bacterial InfectionsHost Defense Against Bacterial InfectionInflammatory Response To Bacterial InfectionLipopolysaccharide-binding Protein
Apolipoprotein A-I (apoA-I), the main protein component of high density lipoprotein (HDL), is well recognized for its antiatherogenic, antioxidant, and antiinflammatory properties. Here, we report a novel role for apoA-I as a host defense molecule that contributes to the complement-mediated killing of an important gastrointestinal pathogen, Gram-negative bacterium Yersinia enterocolitica. We specifically show that the C-terminal domain of apoA-I is the effector site providing the bactericidal activity. Although the presence of the lipopolysaccharide O-antigen on the bacterial surface is absolutely required for apoA-I to kill the bacteria, apoA-I does not interact with the bacteria directly. To the contrary, exposure of the bacteria by serum proteins triggers apoA-I deposition on the bacterial surface. As our data show that both purified lipid-free and HDL-associated apoA-I displays anti-bacterial potential, apoA-I mimetic peptides may be a promising therapeutic agent for the treatment of certain Gram-negative infections. Apolipoprotein A-I (apoA-I), the main protein component of high density lipoprotein (HDL), is well recognized for its antiatherogenic, antioxidant, and antiinflammatory properties. Here, we report a novel role for apoA-I as a host defense molecule that contributes to the complement-mediated killing of an important gastrointestinal pathogen, Gram-negative bacterium Yersinia enterocolitica. We specifically show that the C-terminal domain of apoA-I is the effector site providing the bactericidal activity. Although the presence of the lipopolysaccharide O-antigen on the bacterial surface is absolutely required for apoA-I to kill the bacteria, apoA-I does not interact with the bacteria directly. To the contrary, exposure of the bacteria by serum proteins triggers apoA-I deposition on the bacterial surface. As our data show that both purified lipid-free and HDL-associated apoA-I displays anti-bacterial potential, apoA-I mimetic peptides may be a promising therapeutic agent for the treatment of certain Gram-negative infections.
39
Relation of Helicobacter pylori infection and coronary heart disease.
Michael A. Mendall, Patrick Goggin, N. Molineaux et al. · Heart · 1994 · 663 citations · Full text